Pharmacogenomic Decision Support With GeneSight Psychotropic to Guide the Treatment of Major Depressive Disorder
Phase 4
Completed
- Conditions
- Depressive DisorderDepressionDepressive Disorder, Major
- Interventions
- Genetic: Enhanced-GeneSight Psychotropic (E-GEN)Genetic: GeneSight Psychotropic (GEN)Other: Treatment as Usual (TAU)
- First Posted Date
- 2015-06-09
- Last Posted Date
- 2020-04-30
- Lead Sponsor
- Assurex Health Inc.
- Target Recruit Count
- 542
- Registration Number
- NCT02466477
- Locations
- ๐จ๐ฆ
London Health Sciences Centre, London, Ontario, Canada
๐จ๐ฆCanadian Phase Onward Inc., Toronto, Ontario, Canada
๐จ๐ฆChatham-Kent Clinical Trials Research Center, Chatham, Ontario, Canada
Genomics Used to Improve DEpression Decisions
Not Applicable
Completed
- Conditions
- Major Depressive Disorder (MDD)
- Interventions
- Genetic: GeneSight Psychotropic
- First Posted Date
- 2014-04-10
- Last Posted Date
- 2020-01-14
- Lead Sponsor
- Assurex Health Inc.
- Target Recruit Count
- 1398
- Registration Number
- NCT02109939
- Locations
- ๐บ๐ธ
Mood and Anxiety Disorders Treatment and Research, Philadelphia, Pennsylvania, United States
๐บ๐ธCiTrials, Riverside, California, United States
๐บ๐ธPharmacology Research Institute, Los Alamitos, California, United States
Retrospective Analysis of Outcomes With a Pharmacogenomic Algorithm
Completed
- Conditions
- DepressionAnxiety
- First Posted Date
- 2012-07-02
- Last Posted Date
- 2016-01-05
- Lead Sponsor
- Assurex Health Inc.
- Target Recruit Count
- 104
- Registration Number
- NCT01632267
- Locations
- ๐บ๐ธ
Union Health Services, Chicago, Illinois, United States
Pharmacogenetic-Directed Treatment for Major Depression
Not Applicable
Completed
- Conditions
- Depression
- Interventions
- Behavioral: GeneSightRxBehavioral: Treatment as usual
- First Posted Date
- 2010-12-16
- Last Posted Date
- 2015-12-03
- Lead Sponsor
- Assurex Health Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT01261364
ยฉ Copyright 2025. All Rights Reserved by MedPath